Why did NeuroSense's net profit plummet in Q3 2024?

NeuroSense Therapeutics experienced a net loss of $2.15 million in Q3 2024, which can be attributed to several factors:

1. **Decrease in Revenue**: The company's total revenue year-on-year growth value for the period ending December 31, 2024, is not available. This lack of information makes it difficult to assess the company's revenue performance and its impact on the net profit. However, it is important to note that the absence of revenue growth or a decrease in revenue can significantly contribute to a net profit decline.
2. **Cost of Goods Sold**: The Cost of Goods Sold (COGS) Yoy Growth value is also not available. Similar to revenue, the absence of COGS data makes it challenging to analyze the company's cost structure and its impact on the net profit. COGS is a significant factor in determining the gross profit, which is a key component of the net profit.
3. **Expenses**: The company's net income statement for Q3 2024 is not available. However, according to the latest available data from Q4 2024, NeuroSense saw a decrease in research and development expenses from $7.3 million in 2023 to $5.7 million in 2024, and general and administrative expenses decreased from $4.8 million to $4.2 million. Despite these reductions, the company still reported a net loss of $10.2 million for 2024, which suggests that the expenses may not be the sole reason for the net profit decline.
4. **Financial Challenges**: NeuroSense has been facing severe financial challenges, including the lack of revenue and profitability, and a weak balance sheet. These financial constraints could have led to a net profit decline even in the absence of specific expense reductions.

In conclusion, the net profit decline in Q3 2024 for NeuroSense Therapeutics is likely a result of a combination of factors, including a decrease in revenue, cost of goods sold, and ongoing financial challenges. The absence of specific data for revenue and cost of goods sold growth values limits a more detailed analysis.